• Users Online: 426
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 33  |  Issue : 1  |  Page : 1-5

Vitamin D receptor and cathelicidin expressions in children with atopic dermatitis


1 Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Zahraa Univerisity Hospital, Al-Azhar University, Cairo, Egypt
2 Department of Clinical Biochemistry, Cairo University, Cairo, Egypt

Correspondence Address:
Hanan M. Darwish
MD, Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Zahraa Univerisity Hospital, Al-Azhar University, Abbasia, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7123/01.EJDV.0000430804.31381.9c

Rights and Permissions

Background

Atopic dermatitis (AD) is a common chronic inflammatory type of eczema. Vitamin D may enhance the innate immune response by induction of cathelicidin (LL-37), an endogenous antimicrobial peptide. Several recent reports suggest a connection between vitamin D3 and the expression of antimicrobial peptides in keratinocytes. 1,25-dihydroxyvitamin D (1,25(OH)2D3) is the active form of vitamin D and exerts its actions through a specific intracellular vitamin D receptor (VDR).

Aim

To evaluate the expression of VDR and cathelicidin in children with AD in Egypt.

Methods

The study was carried out on 15 patients with AD and 15 healthy controls. Patients were divided into mild, moderate, and severe groups according to the SCORAD score. All individuals were subjected to skin biopsy. VDR and cathelicidin expressions were estimated using real-time PCR in patients and controls.

Results

A highly significant difference was detected between patients and controls in VDR and cathelicidin expression (P=0.001). A statistically significant correlation was observed between VDR and cathelicidin expressions.

Conclusions

Influencing cathelicidin expression by targeting the vitamin D3 pathway might present a novel therapeutic approach for the treatment of AD.



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed746    
    Printed25    
    Emailed0    
    PDF Downloaded125    
    Comments [Add]    

Recommend this journal